Latest Healthcare News

Skin Elements Limited advances its natural biotechnology products with ECO-Nurture trials concluding and SuprCuvr disinfectant gaining traction, supported by a successful $656k capital raise.

UNITH Ltd reports a 9.3% rise in Q3 FY25 cash receipts driven by its B2C subscription surge and a landmark pharmaceutical contract, alongside strategic platform upgrades and leadership changes.

Enlitic reported a 5.8% revenue increase in Q1 CY25, strengthened its collaboration with GE HealthCare, and accelerated integration of Laitek, positioning itself for operational cashflow break-even by the end of 2025.

D3 Energy’s latest quarterly report reveals a promising new helium production province at its ER315 permit, alongside expanded exploration permits and preparations for a key Production Right application.

Oakridge International Limited reported strong operational and financial progress for Q1 2025, highlighting increased trading income, positive cash flow, and a robust sales pipeline in healthcare IoT technology despite ongoing legal discussions.

Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.

Imagion Biosystems has progressed its MagSense HER2 breast cancer imaging agent towards a pivotal Investigational New Drug application with the FDA, backed by a solid funding runway exceeding 13 quarters.

InteliCare Holdings has secured a new commercial trial with mecwacare and advanced deployments at Hardi Aged Care sites, underpinning growth in its AI-driven aged care platform amid regulatory changes.

TrivarX has launched a pivotal mental health clinical trial in partnership with the US Department of Veterans Affairs, leveraging its innovative ECG-based technology to screen for major depressive episodes. The company also secured $2.25 million in funding, positioning it for regulatory milestones ahead.

IMEXHS Limited reported modest revenue growth and a 16% increase in ARR in Q1 FY25, alongside the commercial rollout of its Aquila+ radiology platform and a $2.5 million capital raising to fuel expansion.

Mesoblast has commercially launched Ryoncil in the US for pediatric acute GVHD, backed by a strong cash position and advancing multiple cell therapy programs.

Genetic Signatures Ltd reported a robust 71% jump in quarterly sales to $2.9 million, fueled by strong respiratory testing demand in Australia and key US commercial contracts. The company is advancing its automation and instrument customisation strategy to streamline molecular diagnostics offerings.